Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer

Status Terminated

Clinical Trial Summary

The overall aim of this feasibility study is to develop new technologies for improved detection of cholangiocarcinoma using the SFE-based molecular-imaging mini-cholangioscope (MC) system. This study will combine the use of a fluorescent-labeled peptide dimer that binds specifically to know biomarkers of cholangiocarcinoma for use as a novel imaging agent to guide endoscopic biopsies. This Phase 1B study will be used to provide early evidence of efficacy for the topical application of a peptide dimer that binds to molecular targets that are specific for biliary intra-epithelial neoplasia. A dimer is needed because cancer in the biliary tract is genetically heterogeneous. QRH binds specifically to Epidermal Growth Factor Receptor (EGFR), and KSP binds specifically to Human Epithelial Growth Factor Receptor (HER2). The study will look at peptide binding in subjects having a medical condition requiring an ERCP to diagnose a potential biliary disorder. The Phase 1A first-in-human studies of safety with topical administration by ingestion of KSP/QRH dimer (HUM00141420) has been completed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cholangiocarcinoma

Clinical Trial Details

NCT number	NCT04304781
Study type	Interventional
Source	University of Michigan
Contact
Status	Terminated
Phase	Phase 1
Start date	September 22, 2020
Completion date	December 17, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05497531` - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	N/A
Recruiting	`NCT05678218` - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Recruiting	`NCT06010862` - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors	Phase 1
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Recruiting	`NCT05179486` - Molecular Epidemiology of Biliary Tree Cancers
Suspended	`NCT05124743` - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Completed	`NCT03150615` - Enteral Nutrition After Pancreaticoduodenectomy	N/A
Completed	`NCT01912053` - Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma	Phase 2
Recruiting	`NCT01439698` - Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry	N/A
Terminated	`NCT01434459` - Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin	Phase 1
Completed	`NCT01206049` - Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations	Phase 2
Recruiting	`NCT00973713` - Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol	Phase 2
Terminated	`NCT00975039` - Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma	Phase 2
Completed	`NCT00779454` - Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma	Phase 2
Terminated	`NCT04066491` - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC	Phase 2/Phase 3
Recruiting	`NCT04340986` - Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
Active, not recruiting	`NCT04526106` - REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03603834` - Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma	Phase 2
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A